-
公开(公告)号:US20070134246A1
公开(公告)日:2007-06-14
申请号:US11700711
申请日:2007-01-30
申请人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
发明人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
IPC分类号: A61K39/395 , C07K16/22
CPC分类号: C07K16/22 , A61K2039/505 , A61P13/12 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
摘要翻译: 本发明涉及抗体分子,特别是结合转化生长因子β(TGFβ)的抗体分子及其用途。 更具体地,本发明涉及结合并优选中和TGFbeta1,TGFbeta2和TGFbeta3,所谓的“泛特异性”抗体分子的抗体分子,以及这种抗体分子的用途。 本发明中优选的实施方案是抗体分子,无论是全抗体(例如IgG,如IgG1或IgG4)还是抗体片段(例如scFv,Fab,dAb)。
-
公开(公告)号:US20070264255A1
公开(公告)日:2007-11-15
申请号:US11700684
申请日:2007-01-30
申请人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
发明人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
IPC分类号: A61K39/395 , C07H21/04 , C07K16/18 , C12N5/06 , C12P1/00
CPC分类号: C07K16/22 , A61K2039/505 , A61P13/12 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
摘要翻译: 本发明涉及抗体分子,特别是结合转化生长因子β(TGFβ)的抗体分子及其用途。 更具体地,本发明涉及结合并优选中和TGFbeta1,TGFbeta2和TGFbeta3,所谓的“泛特异性”抗体分子的抗体分子,以及这种抗体分子的用途。 本发明中优选的实施方案是抗体分子,无论是全抗体(例如IgG,如IgG1或IgG4)还是抗体片段(例如scFv,Fab,dAb)。
-
公开(公告)号:US20060251658A1
公开(公告)日:2006-11-09
申请号:US11350906
申请日:2006-02-08
申请人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
发明人: Steven Ledbetter , Celia Hart , Robert Holgate , Lutz Jermutus , Catriona Buchanan , Alexander Duncan , Donna Finch
IPC分类号: A61K39/395 , C07H21/04 , C12P21/06 , C07K16/22 , C12N5/06
CPC分类号: C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
摘要翻译: 本发明涉及抗体分子,特别是结合转化生长因子β(TGFβ)的抗体分子及其用途。 更具体地,本发明涉及结合并优选中和TGFbeta1,TGFbeta2和TGFbeta3,所谓的“泛特异性”抗体分子的抗体分子,以及这种抗体分子的用途。 本发明中优选的实施方案是抗体分子,无论是全抗体(例如IgG,如IgG1或IgG4)还是抗体片段(例如scFv,Fab,dAb)。
-
公开(公告)号:US20130149312A1
公开(公告)日:2013-06-13
申请号:US13641406
申请日:2011-04-18
申请人: Donna Finch , Anthony Coyle , Martin Stampfli
发明人: Donna Finch , Anthony Coyle , Martin Stampfli
IPC分类号: A61K39/395 , A61K31/56
CPC分类号: A61K39/3955 , A61K31/56 , A61K38/2006 , A61K2039/505 , C07K16/2866 , C07K2317/56
摘要: This disclosure relates to methods of treating exacerbation of chronic obstructive pulmonary disease (COPD) with antibodies and antagonists to interleukin 1 receptor 1 (IL-1R1) or IL-1α.
摘要翻译: 本公开涉及用白细胞介素1受体1(IL-1R1)或IL-1α的抗体和拮抗剂治疗慢性阻塞性肺病(COPD)恶化的方法。
-
-
-